Latest news

Thumbnail image for Priority review for Shire’s HAE drug

Priority review for Shire’s HAE drug

US regulators are undertaking a speedy review of Shire’s lanadelumab (SHP643) for the prevention of angioedema attacks in patients 12 years and older with hereditary angioedema (HAE).

23rd February 2018

Thumbnail image for Finalists soon to be revealed!

Finalists soon to be revealed!

Clinical researchers the world over have submitted essays for this year's competition and yesterday, the authors and finalists were identified at a special meeting of the executive steering group

23rd February 2018

Thumbnail image for NICE sticks with ‘no’ for earlier use of Halaven

NICE sticks with ‘no’ for earlier use of Halaven

Cost regulators for NHS treatments in England and Wales are sticking with their position that Eisai’s Halaven should not be funded by the NHS as a second-line of attack against a certain form of breast cancer.

22nd February 2018

Thumbnail image for Major study backs efficacy of antidepressants

Major study backs efficacy of antidepressants

A large-scale review of the most common antidepressants has found them all to be superior to placebo in treating major depression, potentially laying to rest questions over their effectiveness.

22nd February 2018

Thumbnail image for Arix ties with Ipsen

Arix ties with Ipsen

London, UK-based Arix Bioscience has entered into a strategic agreement with French drugmaker Ipsen to develop and commercialise innovative therapies.

22nd February 2018

Thumbnail image for Merck buys Australia’s Viralytics

Merck buys Australia’s Viralytics

Merck & Co is broadening its immuno-oncology offering through the purchase of Australian group Viralytics in a deal worth $394 million.

21st February 2018

Previous  --   8 9 10 11 12 13 14 15 16 17   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download